Search Results
371 items found for "Xiaoxia Li"
- PAR-Induced Harnessing of EZH2 to β-Catenin: Implications for Colorectal Cancer
correlated with high PAR4-driven tumors, and is abundantly expressed in large tumors, whereas very little
- Immunomodulatory Role of Neuropeptides in the Cornea
regarding the details of neuropeptide signaling and how it contributes to pathophysiology, which is likely of corneal diseases with promising results, necessitating the need for a comprehensive review of the literature
- Biased GPCR signaling by the native parathyroid hormone-related protein 1 to 141 relative to its...
transient cAMP production, acute intracellular Ca2+ (iCa2+) release and β-arrestin recruitment mediated by ligand-PTHR
- Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells...
As therapeutic options are limited, novel targets and agents for therapeutic intervention are urgently
- Trainees, this is for you...
Would you like to develop your presentation skills? Give a talk or present a poster at the Dr.
- Carola Weiss joins InterAx Biotech AG as VP Business Development
Carola Weiss’ professional career brings deep expertise in business development, marketing & sales, licensing
- Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline ...
England & BOSTON--Sanofi and Exscientia announced today a groundbreaking research collaboration and license The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia’s novel
- Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine...
DIEGO, Dec. 7, 2021 /PRNewswire/ -- Neurocrine Biosciences (Nasdaq: NBIX) today announced positive top-line
- ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated ...
receive marketing authorization in all member states of the European Union, as well as in Iceland, Liechtenstein
- Murine bone marrow macrophages and human monocytes do not express atypical chemokine receptor 1
Erythrocytes are terminally differentiated anuclear cells with no transcription and limited translation Accordingly, within the erythroid lineage ACKR1 expression occurs first and is the highest in erythroblasts venular endothelial cells (ECs) ( Pruenster et al., 2009 ; Thiriot et al., 2017 ), including those lining macrophages, but not erythroblasts and ECs, suggesting that macrophage ACKR1 engages its non-cognate ligand In light of the extensive literature, these findings have been particularly provocative, as this was
- 8th RSC / SCI symposium on GPCRs in Medicinal Chemistry. October 5-7, 2022, Verona, Italy
Wednesday-Friday, 5th-7th October 2022 Place Evotec Campus Levi-Montalcini, Verona, Italy Downloads and Links
- Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares
Cancer Research UK, a charity dedicated to funding lifesaving oncology research, spent £388 million on
- Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in...
clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living
- 4GPCRnet, September 26-29, 2022. Leipzig, Germany
will take place in the heart of Leipzig, which offers a colorful mixture of culture and vivid social life
- Pharmacophore-guided Virtual Screening to Identify New β 3 -adrenergic Receptor Agonists
It is a therapeutic target because it plays a role in thermogenesis, lipolysis, and bladder relaxation Ligand-based pharmacophore modeling was performed since no 3D structure of human β3 -AR is yet available
- Crinetics Presents Clinical And Research Results At ENDO 2022
serum cortisol levels and 24-hour urine free cortisol excretion in the presence of sustained, disease-like
- Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR
discovery involving the gut-brain axis, will gain unique and valuable access to the Sosei Heptares compound library
- Targeting the M1 muscarinic receptor in neurodegenerative disease
cognitive and neurodegenerative disorders and the potential therapeutic benefit of muscarinic M1 selective ligands
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
Vraniak’s career spans more than 20 years of financial and commercial experience in the life sciences
- Domain Therapeutics Raises $42m Series A Financing
announced today the closing of a US $42m (€39m) series A financing round co-led by Panacea Venture, CTI Life
- Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of ...
Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like
- Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
structure-based drug design platform and enhancing translational medicine capabilities • ‘Venture-like value generation • Mid-term global expansion plans include drug discovery technology investments, licensing
- Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with ...
explored for treating central nervous system and neurologic disorders, particularly movement disorders like
- Mark Schmeizl - Dr. GPCR Podcast
He is a pro at Matchmaking the top talent in the life sciences with the industry’s leading companies. Listen where you get your podcasts https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ #drgpcr #gpcr #podcast
- ShouTi Pharma has a brand new website
experienced, innovative, global team on a bold mission to improve health by creating and developing life-changing
- Rhodopsin as a Molecular Target to Mitigate Retinitis Pigmentosa
Currently, there is no cure for RP, and the therapeutic options are limited.
- Targeted Activation of G-Protein Coupled Receptor-Mediated Ca 2+ Signaling Drives Enhanced Cartilage
and synthetically initiate robust [Ca2+]i transients and oscillatory [Ca2+]i signaling in chondrocyte-like receptor (GPCR)-mediated [Ca2+]i signaling involvement in chondroprogenitor proliferation and cartilage-like
- G-protein-coupled receptors as therapeutic targets for glioblastoma
Despite this, the prognosis remains poor, with an impacted quality of life during treatment coupled with